Drug · DIN 02437341
ICLUSIG
Authorized, but not sold for a year or more
Authorized, but the company reports it has not been sold in Canada for at least 12 months.
Status Dormant since August 8, 2022; first marketed January 7, 2016.
- Drug Identification Number (DIN)
- 02437341
- Company (DIN owner)
- Takeda Pharmaceuticals U.S.A., Inc.Cambridge, Massachusetts, United States
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Ponatinib L01EA05
- Class
- Human
- Record last updated
- July 11, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PONATINIB (PONATINIB HYDROCHLORIDE) | 45 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 8, 2022: NOC 28710New Drug Submission (NDS) · Administrative: Merger/Buy-out
- April 2, 2015: NOC 16753New Drug Submission (NDS)
Other DINs named ICLUSIG
- DIN 02437333 · Marketed